Research programme: cannabinoid/naproxen conjugate - Claritas Pharmaceuticals
Latest Information Update: 28 Apr 2022
At a glance
- Originator Beetlebung Pharma
- Developer Claritas Pharmaceuticals
- Class Analgesics; Cannabinoids; Drug conjugates
- Mechanism of Action Cannabinoid receptor agonists; Dinoprostone antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute pain